Adjuvant accelerated partial-breast irradiation of early-stage breast cancer using stereotactic approach – methodology, technical challenges and early results of prospective randomized trial

Czech version

Authors: P. Burkoň ¹; I. Selingerová ²; M. Slavik ¹; M. Holánek ³; M. Vrzal ¹; T. Kazda ^1,2; V. Hůlková ¹; M. Blažková ¹; K. Poláchová ¹; P. Šlampa ¹
Authors‘ workplace: Klinika radiační onkologie LF MU a MOÚ Brno ¹; Výzkumné centrum aplikované molekulární onkologie (RECAMO), MOÚ Brno ²; Klinika komplexní onkologické péče LF MU a MOÚ Brno ³
Published in: Klin Onkol 2022; 35(5): 379-391
Category: Original Articles
doi: https://doi.org/10.48095/ccko2022379

Overview

Background: The adjuvant radiotherapy (RT) of the early-stage breast cancer patients as local treatment aims to eliminate potential microscopic residual disease in the surgery bed or satellites in its neighborhood. Based on published studies, accelerated partial breast irradiation (APBI) is recommended for strictly selected patients. The aim of this single-institution prospective randomized study was to compare the targeted APBI delivered by stereotactic approach with the currently more commonly used accelerated whole breast irradiation with the boost to the tumor bed in terms of feasibility, safety, tolerance, and cosmetic effects. Materials and methods: Early-stage breast cancer patients after partial mastectomy were screened for eligibility. The inclusion criteria were age > 50 years, non-lobular carcinoma histology, size ≤ 2 cm, negative margins ≥ 2 mm, L0, ER-positive, BRCA negative. Enrolled patients were equally randomized into two arms according to radiotherapeutic regiment – external APBI (5× 6 Gy) and accelerated whole breast irradiation with the boost (15× 2,67 Gy + 5× 2 Gy). These preliminary results of the ongoing study evaluated the first 57 from 84 planned patients. Results: The median age was 65 years. The tumors were of grade 1 in 60 % of patients, the median size of 9 mm and 70 % were classified as invasive ductal carcinoma. Statistical significant differences between the groups in baseline characteristics were not observed. A total of 29 patients was enrolled in the APBI group by the end of 2020. All enrolled patients were evaluated one month after RT. A total of 40 (70,2 %) a 33 (58 %) had examinations 3 and 6 months after RT, respectively. Toxicity evaluation showed statistically significantly fewer acute adverse events in the APBI group in terms of skin erythema, desquamation, skin tenderness, dryness, edema, pigmentation, breast pain and fatigue. Late toxicity evaluated in 3 and 6 months after RT was significantly higher in the control group. The cosmetic effect (independently evaluated by a physician, nurse and patient) was more favorable to the APBI group. Conclusion: The technique using the principles of targeted radiotherapy turned out to be a less toxic and easier feasible approach for adjuvant radiation of early-stage breast cancer patients. Consequently, the presented study increases the level of evidence for RT-indicated patients to the establishment of external APBI into daily clinical practice.

Keywords:

breast cancer – stereotactic body radiotherapy – early stages – adjuvant radiotherapy – surgical bed – APBI

Sources

1. Livi L, Meattini I, Marrazzo L et al. Accelerated partial breast irradiation using intensity – modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. Eur J Cancer 2015; 51 (4): 451–463. doi: 10.1016/j.ejca.2014.12.013.

2. Meattini I, Saieva C, Marrazzo L et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Res Treat 2015; 153 (3): 539–547. doi: 10.1007/s10549-015-3565-2.

3. Rodriguez N, Sanz X, Dengra J et al. Five-year outcomes, cosmesis, and toxicity with 3- dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys 2013; 87 (5): 1051–1057. doi: 10.1016/j.ijrobp.2013.08.046.

4. Strnad V, Ott OJ, Hildebrandt G et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet 2016; 387 (10015): 229–238. doi: 10.1016/S0140-6736 (15) 00 471-7.

5. Schäfer R, Strnad V, Polgar C et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncol 2018; 19 (6): 834–844. doi: 10.1016/S1470-2045 (18) 30195-5.

6. Polgár C, Ott OJ, Hildebrandt G et al. Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncol 2017; 18 (2): 259–268. doi: 10.1016/S1470-2045 (17) 30011-6.

7. Ott OJ, Strnad V, Hildebrandt G et al. GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiother Oncol 2016; 120 (1): 119–123. doi: 10.1016/j.radonc.2016.06.019.

8. Correa C, Harris EE, Leonardi MC et al. Accelerated partial breast irradiation: executive summary for the update of an ASTRO evidence based consensus statement. Pract Radiat Oncol 2017; 7 (2): 73–79. doi: 10.1016/j.prro.2016.09.007.

9. Strnad V, Major T, Polgar C et al. ESTRO-ACROP guideline: interstitial multi-catheter breast brachytherapy as accelerated partial breast irradiation alone or as boost – GEC-ESTRO breast cancer working group practical recommendations. Radiother Oncol 2018; 128 (3): 411–420. doi: 10.1016/j.radonc.2018.04.009.

10. Strnad V, Krug D, Sedlmayer F et al. DEGRO practical guideline for partial-breast irradiation. Strahlenther Onkol 2020; 196 (9): 749–763. doi: 10.1007/s00066-020-01613-z.

11. Keisch M, Vicini F, Kuske R et al. Initial clinical experience with the MammoSite breast brachytherapy applicator in women with early stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys 2003; 55 (2): 289–293. doi: 10.1016/s0360-3016 (02) 04277-3.

12. Formenti S, Rosenstein B, Skinner K et al. T1 stage breast cancer: adjuvant hypofractionated conformal radiation therapy to tumor bed in selected postmenopausal breast cancer patients a pilot feasibility study. Radiology 2002; 222 (1): 171–178. doi: 10.1148/radiol.2221010769.

13. Livi L, Meattini I, Marrazzo L et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. Eur J Cancer 2015; 51 (4): 451–463. doi: 10.1016/j.ejca.2014.12.013.

14. Meattini I, Saieva C, Miccinesi G et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. Eur J Cancer 2017; 76: 17–26. doi: 10.1016/j.ejca.2017.01.023. Epub 2017 Mar 3.

15. Bondiau P, Bahadoran P, Lallement M et al. Robotic stereotactic radioablation concomitant with neo-adjuvant chemotherapy for breast tumors. Int J Radiat Oncol Biol Phys 2009; 75 (4): 1041–1047. doi: 10.1016/ j.ijrobp.2008.12.037.

16. Hepel J, Tokita M, MacAusland S et al. Toxicity of three-dimensional conformal radiotherapy for accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys 2009; 75 (5): 1290–1296. doi: 10.1016/j.ijrobp.2009.01.009.

17. Jagsi R, Ben-David M, Moran J et al. Unacceptable cosmesis in a protocol investigating intensity-modulated radiotherapy with active breathing control for accelerated partial-breast irradiation. Int J Radiat Oncol Biol Phys 2009; 76 (1): 71–78. doi: 10.1016/j.ijrobp.2009.01.041.

18. Olivotto I, Whelan T, Parpia S et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. J Clin Oncol 2013; 31 (32): 4038–4045. doi: 10.1200/JCO.2013.50.5511.

19. Šlampa P. Radiační onkologie. Maxdorf: Jessenius 2021.

20. Bergom C, Currey A, Desai N et al. Deep inspiration breath hold: techniques and advantages for cardiac sparing during breast cancer irradiation. Front Oncol 2018; 8: 87. doi: 10.3389/fonc.2018.00087.

21. Latty D, Stuart KE, Wang W et al. Review of deep inspiration breath-hold techniques for the treatment of breast cancer. J Med Radiat Sci 2015; 62 (1): 74–81. doi: 10.1002/jmrs.96.

22. Otto K. Volumetric modulated arc therapy: IMRT in a single gantry arc. Med Phys 2008; 35 (1): 310–317. doi: 10.1118/1.2818738.

23. Yan Y, Yadav P, Bassetti M et al. Dosimetric differences in flattened and flattening filter-free beam treatment plans. J Med Phys 2016; 41 (2): 92–99. doi: 10.4103/0971-6203.181636.

24. Schmidhalter D, Fix MK, Wyss M et al. Evaluation of a new six degrees of freedom couch for radiation therapy. Med Phys 2013; 40 (11): 111710. doi: 10.1118/1.4823789.

25. Haviland JS, Hopwood P, Mills J et al. Do patient-reported outcome measures agree with clinical and photographic assessments of normal tissue effects after breast radiotherapy? The experience of the Standardisation of Breast Radiotherapy (START) trials in early breast cancer. Clin Oncol 2016; 28 (6): 345–353. doi: 10.1016/j.clon.2016.01.011.

26. Bergom C, Currey A, Desai N et al. Deep inspiration breath hold: techniques and advantages for cardiac sparing during breast cancer irradiation. Front Oncol 2018; 8: 87. doi: 10.3389/fonc.2018.00087.

27. Latty D, Stuart KE, Wang W et al. Review of deep inspiration breath-hold techniques for the treatment of breast cancer. J Med Radiat Sci 2015; 62 (1): 74–81. doi: 10.1002/jmrs.96.

28. Burkon P, Slampa P, Kazda T et al. Stereotactic body radiation therapy for colorectal cancer liver metastases; early results. Klin Onkol 2012; 25 (Suppl 2): 2S93–2S97.

29. Burkon P, Kazda T, Pospisil P et al. Ablative dose stereotactic body radiation therapy for oligometastatic disease: a prospective single institution study. Neoplasma 2019; 66 (2): 315–325. doi: 10.4149/neo_2018_180731N558.

30. Burkon P, Selingerova I, Slavik M et al. Stereotactic body radiotherapy for lymph node oligometastases: real-world evidence from 90 consecutive patients. Front Oncol 2021; 10: 616494. doi: 10.3389/fonc.2020.616494.

31. Burkoň P, Oberreiterová S, Kazda T et al. Stereotactic body radiotherapy of lymph node oligometastases. Klin Onkol 2020; 33 (2): 114–122. doi: 10.14735/amko2020 114.

32. Formenti S, Rosenstein B, Skinner K et al. T1 stage breast cancer: adjuvant hypofractionated conformal radiation therapy to tumor bed in selected postmenopausal breast cancer patients a pilot feasibility study. Radiology 2002; 222 (1): 171–178. doi: 10.1148/radiol.2221010769.

33. Otto K. Volumetric modulated arc therapy: IMRT in a single gantry arc. Med Phys 2008; 35 (1): 310–317. doi: 10.1118/1.2818738.

34. Ong CL, Verbakel WF, Cuijpers JP et al. Stereotactic radiotherapy for peripheral lung tumors: a comparison of volumetric modulated arc therapy with 3 other delivery techniques. Radiother Oncol 2010; 97 (3): 437–442. doi: 10.1016/j.radonc.2010.09.027.

35. Yan Y, Yadav P, Bassetti M et al. Dosimetric differences in flattened and flattening filter-free beam treatment plans. J Med Phys 2016; 41 (2): 92–99. doi: 10.4103/0971-6203.181636.

36. Purdie TG, Bissonnette JP, Franks K et al. Cone-beam computed tomography for on-line image guidance of lung stereotactic radiotherapy: localization, verification, and intrafraction tumor position. Int J Radiat Oncol Biol Phys 2007; 68 (1): 243–252. doi: 10.1016/j.ijrobp.2006.12.022.

37. Formenti S, Rosenstein B, Skinner K et al. T1 stage breast cancer: adjuvant hypofractionated conformal radiation therapy to tumor bed in selected postmenopausal breast cancer patients a pilot feasibility study. Radiology 2002; 222 (1): 171–178. doi: 10.1148/radiol.2221010769.

38. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85 (5): 365–376. doi: 10.1093/jnci/85.5.365.

39. Sprangers MA, Groenvold M, Arraras JI et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol 1996; 14 (10): 2756–2768. doi: 10.1200/JCO.1996.14.10.2756.

40. Haloua MH, Krekel NMA, Jacobs GJA et al. Cosmetic outcome assessment following breast-conserving therapy: a comparison between BCCT.core software and panel evaluation. Int J Breast Cancer 2014; 2014: 716860. doi: 10.1155/2014/716860.

41. Darby S, McGale P, Correa C et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011; 378 (9804): 1707–1716. doi: 10.1016/S0140-6736 (11) 61629-2.

42. Bartelink H, Horiot J, Poortmans P et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 2001; 345 (19): 1378–1387. doi: 10.1056/NEJMoa010874.

43. Fisher B, Anderson S, Bryant J et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002; 347 (16): 1233–1241. doi: 10.1056/NEJMoa022152.

44. Veronesi U, Marubini E, Mariani L et al. Radiotherapy after breast conserving surgery in small breast carcinoma: long-term results of a randomized trial. Ann Oncol 2001; 12 (7): 997–1003. doi: 10.1023/a: 1011136326943.

45. Correa C, Harris EE, Leonardi MC et al. Accelerated partial breast irradiation: executive summary for the update of an ASTRO evidence-based consensus statement. Pract Radiat Oncol 2017; 7 (2): 73–79. doi: 10.1016/j.prro.2016.09.007.

46. Strnad V, Major T, Polgar C et al. ESTRO-ACROP guideline: interstitial multi-catheter breast brachytherapy as accelerated partial breast irradiation alone or as boost – GEC-ESTRO breast cancer working group practical recommendations. Radiother Oncol 2018; 128 (3): 411–420. doi: 10.1016/j.radonc.2018.04.009.

47. Strnad V, Krug D, Sedlmayer F et al. DEGRO practical guideline for partial-breast irradiation. Strahlenther Onkol 2020; 196 (9): 749–763. doi: 10.1007/s00066-020-01 613-z.

48. Veronesi U, Orecchia R, Maisonneuve P et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol 2013; 14 (13): 1269–1277. doi: 10.1016/S1470-2045 (13) 70497-2.

49. Vaidya JS, Wenz F, Bulsara M et al. TARGIT trialists’ group. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet 2014; 383 (9917): 603–613. doi: 10.1016/S0140-6736 (13) 61950-9.

50. Nachbar M, Mönnich D, Boeke S et al. Partial breast irradiation with the 1.5 T MR-Linac: first patient treatment and analysis of electron return and stream effects. Radiother Oncol 2019; 145: 30–35. doi: 10.1016/j.radonc.2019.11.025.

51. Bennion NR, Baine M, Granatowicz A et al. Accelerated partial breast radiotherapy: a review of the literature and future directions. Gland Surg 2018; 7 (6): 596–610. doi: 10.21037/gs.2018.11.05.

52. Strnad V, Ott OJ, Hildebrandt G et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet 2016; 387 (10015): 229–238. doi: 10.1016/S0140-6736 (15) 00 471-7.

53. Polgár C, Fodor J, Major T et al. Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiother Oncol 2013; 108 (2): 197–202. doi: 10.1016/j.radonc.2013.05.008.

54. Ott OJ, Strnad V, Hildebrandt G et al. GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiother Oncol 2016; 120 (1): 119–123. doi: 10.1016/j.radonc.2016.06.019.

55. Polgár C, Ott OJ, Hildebrandt G et al. Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncol 2017; 18 (2): 259–268. doi: 10.1016/S1470-2045 (17) 30011-6.

56. White J, Winter K, Kuske RR et al. Long-term cancer outcomes from study NRG oncology/ RTOG 9517: a phase 2 study of accelerated partial breast irradiation with multicatheter brachytherapy after lumpectomy for early-stage breast cancer. Int J Radiat Oncol Biol Phys 2016; 95 (5): 1460–1465. doi: 10.1016/j.ijrobp.2016.03. 037.

57. Rabinovitch R, Winter K, Kuske R et al. RTOG 95-17, a phase II trial to evaluate brachytherapy as the sole method of radiation therapy for stage I and II breast carcinoma – year-5 toxicity and cosmesis. Brachytherapy 2014; 13 (1): 17–22. doi: 10.1016/j.brachy.2013.08.002.

58. Schäfer R, Strnad V, Polgar C et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncol 2018; 19 (6): 834–844. doi: 10.1016/S1470-2045 (18) 30195-5.

59. Kamrava M, Kuske RR, Anderson B et al. Outcomes of breast cancer patients treated with accelerated partial breast irradiation via multicatheter interstitial brachytherapy: the pooled registry of multicatheter interstitial sites (PROMIS) experience. Ann Surg Oncol 2015; 22 (Suppl 3): S404–411. doi: 10.1245/s10434-015-4563-7.

60. Rodriguez N, Sanz X, Dengra J et al. Five-year outcomes, cosmesis, and toxicity with 3- dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys 2013; 87 (5): 1051–1057. doi: 10.1016/j.ijrobp.2013.08. 046.

61. Coles CE, Griffin CL, Kirby AM et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet 2017; 390 (10099): 1048–1060. doi: 10.1016/S0140-6736 (17) 31145-5.

62. Livi L, Meattini I, Marrazzo L et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. Eur J Cancer 2015; 51 (4): 451–463. doi: 10.1016/j.ejca.2014.12.013.

63. Meattini I, Saieva C, Marrazzo L et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Res Treat 2015; 153 (3): 539–547. doi: 10.1007/s10549-015-35 65-2.

64. Livi L, Meattini I, Marrazzo L et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. Eur J Cancer 2015; 51 (4): 451–463. doi: 10.1016/j.ejca.2014.12.013.

65. Meattini I. Partial breast irradiation may be as effective as whole breast irradiation in preventing recurrence in patients with early breast cancer. In: San Antonio Breast Cancer Symposium. San Antonio, 12th December 2019.

66. Whelan TJ, Julian JA, Berrang TS et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet 2019; 394 (10215): 2165–2172. doi: 10.1016/S0140-6736 (19) 32515-2.

67. Olivotto IA, Whelan TJ, Parpia S et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. J Clin Oncol 2013; 31 (32): 4038–4045. doi: 10.1200/JCO.2013.50.5 511.

68. Meduri B, Baldissera A, Galeandro M et al. OC-0568: accelerated PBI VS standard radiotherapy (IRMA trial): interim cosmetic and toxicity results. Radiother Oncol 2017; 123: S303. doi: 10.1016/S0167-8140 (17) 31008-3.

69. Vicini FA. Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. Abstract GS4-04. In: San Antonio Breast Cancer Symposium. San Antonio, February 2019.

70. Vicini FA, Cecchini RS, White JR et al. Longterm primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet 2019; 394 (10215): 2155–2164. doi: 10.1016/S0140-6736 (19) 32514-0.

71. NSABP B-39, RTOG 0413: A randomized phase III study of conventional whole breast irradiation versus partial breast irradiation for women with stage 0, I, or II breast cancer. Clin Adv Hematol Oncol 2006; 4 (10): 719–721.

72. Bennion NR, Baine M, Granatowicz A et al. Accelerated partial breast radiotherapy: a review of the literature and future directions. Gland Surg 2018; 7 (6): 596–610. doi: 10.21037/gs.2018.11.05.

73. Dutta SW, Showalter SL, Showalter TN et al. Intraoperative radiation therapy for breast cancer patients: current perspectives. Breast Cancer (Dove Med Press) 2017; 9: 257–263. doi: 10.2147/BCTT.S112516.

74. Bonin K, McGuffin M, Presutti R et al. Breast cancer patients’ preferences for adjuvant radiotherapy post lumpectomy: whole breast irradiation vs. partial breast irradiation-single institutional study. J Cancer Educ 2018; 33 (1): 37–43. doi: 10.1007/s13187-016-1016-3.

75. Hoopes DJ, Kaziska D, Chapin P et al. Patient preferences and physician practice patterns regarding breast radiotherapy. Int J Radiat Oncol Biol Phys 2012; 82 (2): 674–681. doi: 10.1016/j.ijrobp.2010.11.077.

76. Qi X, White J, Li X. Is a/b for breast cancer really low? Radiother Oncol 2011; 100 (2): 282–288. doi: 10.1016/j.radonc.2011.01.010.

77. Bartelink H, Maingon P, Poortmans P et al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol 2015; 16 (1): 47–56. doi: 10.1016/S1470-2045 (14) 71156-8.

78. Timmerman R, Paulus R, Galvin J et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010; 303 (11): 1070–1076. doi: 10.1001/jama.2010.261.

79. Rusthoven K, Kavanagh B, Cardenes H et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 2009; 27 (10): 1572–1578. doi: 10.1200/JCO.2008.19.6329.

80. Burkoň P, Slávik M, Kazda T et al. Stereotactic body radiotherapy – current indications. Klin Onkol 2019; 32 (1): 10–24. doi: 10.14735/amko201910.

Labels

Paediatric clinical oncology Surgery Clinical oncology

Spolupachatelé

Gastrointestinal toxicity of systemic oncology immunotherapy

Patient’s benefi ts from physician’s empathy and results of including of empathy development into medical training

Informace z České onkologické společnosti

Exercise as a tool to improve the quality of life of patients after breast cancer treatment

Biphenotypic sinonasal sarcoma – a case report

Oncology wounds – recommendations for care based on multidisciplinary cooperation

Aktuality z odborného tisku

Programmed death-ligand 1 expression in non-small cell lung carcinoma – mechanism of regulation, association with other markers, and therapeutic implication

Article was published in

Clinical Oncology

2022 Issue 5